Genk, Belgium-based DEO, a company focused on data-driven efficiency for the operating room, has closed a €3.65 million funding round.
DEO Secures €3.65 Million in Funding Round
1 min read Premium comments
Secondary#capricornpartners#deo#karista
DEO focuses on “value-based healthcare” and utilizes an artificial intelligence backed platform to enable hospitals to implement operating room “efficiency best practices.” Additionally, DEO provides “data generation and quantification of operating room efficiency, team ergonomics, and financial performance.” All of this information gives surgical teams the opportunity to improve overall performance and reduce surgical costs.
The funding round was led by Leuven, Belgium-based Capricorn Partners via their Capricorn Digital Growth Fund. Capricorn Partners was joined by early-stage venture capital firm Karista, based in Paris-France. Existing shareholders also participated in this funding round, including Hasselt, Belgium-based LRM and the Leuven, Belgium-based imec.istart fund.
Capricorn Partners Investment Associate Antoine D’Hollander commented, “DEO’s vision perfectly aligns with our investment strategy to focus on companies that turn data into actionable insights. Healthcare is primed to benefit from digital solutions that are powered by the convergence of human & artificial intelligence. DEO rises to this challenge with its OR efficiency platform that positively impacts the healthcare ecosystem to ensure safe and affordable care.”
OTW spoke with DEO CFO and Co-Founder Tim Clijmans about the funding. Clijmans told OTW, “The new financing will enable DEO to accelerate business development, build more commercial partnerships in Europe and the US, and strengthen our product offering even further by developing new software applications on top of the existing data platform, including automated technologies.”
Clijmans also discussed the company’s goals for the upcoming year, informing OTW, “The goals for the upcoming year are 1) scale our offering to more surgical specialties, and 2) expand our network of partners in Europe and the US, offering our solution to even more healthcare providers to enable true value-based healthcare.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.